Loss of patent protection has significant effect on US 2nd-qtr drug sales
The impact of patent expires and resulting generic completion is taking a significant toll on the US sales of some leading brands, according to Drugs.com, the on-line clinical drug resource, which yesterday released second quarter 2012 US prescription sales data for the top 100 drugs.
Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top-selling categories. However, Sanofi’s Plavix (clopidogrel) and AstraZeneca’s Seroquel (quetiapine) dipped in the second quarter due to loss of patent protection. Other top brands such as Merck & Co’s Singulair (montelukast sodium), Eisai’s Actos (pioglitazone) and Novartis’ Diovan valsartan) are also due to be impacted by year's end.
Top five drugs by sales, 2nd-qtr 2012
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze